Validation of Chromogranin A Assays in Patients with Neuroendocrine Tumors Abstract #487

Introduction: CgA is the most important biochemical marker for evaluation of NETs. Different assays with different accuracy exist.
Aim(s): To validate three different assays in NET patients.
Materials and methods: We measured CgA in 42 patients using three different assays (Rigshospitalet in-house (RH), NEOLISA and RIA (Euro-Diagnostica)).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Lise Brehm Høj
Keywords: neuroendocrine, CgA, assay

To read results and conclusion, please login ...

Further abstracts you may be interested in

#783 A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is the most important general tumor marker used in the diagnosis and follow-up of patients with neuroendocrine tumors (NET). CgA assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Dr. Henning Grønbæk
#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Valentina Andreasi
#2836 Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Neoplasms: ENETS Center of Excellence Experience
Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Anna Malczewska
#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study
Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Matias Munoz Medel
#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Daria Handkiewicz-Junak
Keywords: CgA, PRRT, prognosis